DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?

BRISTOL MYERS SQUIBB has seventy-seven approved drugs.

There are seventeen US patents protecting BRISTOL MYERS SQUIBB drugs.

There are four hundred and forty-seven patent family members on BRISTOL MYERS SQUIBB drugs in fifty-seven countries and one hundred and seventy-six supplementary protection certificates in fifteen countries.

Summary for Bristol Myers Squibb

International Patents:	447
US Patents:	17
Tradenames:	66
Ingredients:	58
NDAs:	77
Patent Litigation for Bristol Myers Squibb:	See patent lawsuits for Bristol Myers Squibb

Drugs and US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-002	Feb 27, 1998		DISCN	No	No
Bristol Myers Squibb	METAGLIP	glipizide; metformin hydrochloride	TABLET;ORAL	021460-002	Oct 21, 2002		DISCN	Yes	No
Bristol Myers Squibb	RAU-SED	reserpine	TABLET;ORAL	009357-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-002	Dec 28, 2012		RX	Yes	Yes	6,967,208		Y	Y

Expired US Patents for Bristol Myers Squibb

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	MONOPRIL	fosinopril sodium	TABLET;ORAL	019915-004	Mar 28, 1995	4,384,123
Bristol Myers Squibb	VIDEX EC	didanosine	CAPSULE, DELAYED REL PELLETS;ORAL	021183-002	Oct 31, 2000	5,254,539*PED
Bristol Myers Squibb	SUSTIVA	efavirenz	CAPSULE;ORAL	020972-003	Sep 17, 1998	5,811,423
Bristol Myers Squibb	PRAVIGARD PAC (COPACKAGED)	aspirin; pravastatin sodium	TABLET, TABLET, TABLET;ORAL	021387-003	Jun 24, 2003	4,346,227*PED

Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Capsules	200 mg, 250 mg and 400 mg		2004-06-01
	Tablets	30 mg		2005-06-01
	Capsules	100 mg and 150 mg		2010-03-19
	Tablets	0.5 mg and 1 mg		2010-06-14
	Tablets	80 mg and 140 mg		2011-06-16
	Nasal Spray	4 mg/spray		2016-07-15
	Capsules	50 mg, 100 mg and 200 mg		2016-11-03
	Tablets	600 mg		2009-04-09
	Capsules	300 mg		2009-07-20
	Capsules	200 mg		2010-02-16
	Tablets	20 mg, 50 mg, 70 mg and 100 mg		2010-06-28
	Tablets	80 mg and 140 mg		2011-06-17
	Tablets	2.5 mg and 5 mg		2016-12-28

Non-Orange Book US Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,979,694	Cyclic protein tyrosine kinase inhibitors
8,470,854	Lactam-containing compounds and derivatives thereof as factor XA inhibitors
7,338,963	Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
7,189,854	Cyclic protein tyrosine kinase inhibitors

International Patents for Bristol Myers Squibb Drugs

Country	Document Number	Estimated Expiration
Cyprus	1110509
Austria	223719
Australia	779089
Serbia	54559

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB96/053	United Kingdom		PRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621
2014000114	Germany		PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
2016000120	Germany		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713
91020-8 0090020-9	Sweden		PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 20000609

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bristol
• Bristol Myers
• Bristol Myers Squibb
• Bristol-myers Squibb